NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis

ARS Pharmaceuticals, Inc. (SPRY) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SPRY

$4.18

−$0.11 (−2.56%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SPRY with… →

SPRY Key Statistics

As of Oct 21, 2026
Trading
Open
$4.32
Previous Close
$4.29
Day's Range
4.17–4.42
52-Week Range
3.81–13.15
Volume
1.01M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.08
Valuation
Market Cap
$415.69M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.56
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.18
Financials (FY)
Revenue (FY)
$84.28M−5.46%
Net Income (FY)
−$171.30M−2,241.76%
Profit marginThe share of revenue left as profit after all costs and taxes.
−184.24%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
99.45M
1-Year Return
−57.78%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
1.79M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SPRY closed at $4.18, −57.78% over 1 year.

ARS Pharmaceuticals, Inc. (SPRY) has a market capitalization of $415.69M.

In fiscal 2025, SPRY reported revenue of $84.28M.

SPRY Stock Return by Calendar Year

ARS Pharmaceuticals, Inc. (SPRY) return since Dec 2020: what $10,000 became

1 year
$10,000 $4,222
−57.78%
5 years
$10,000 $4,499
−55.01%
Since Dec 2020
$10,000 $1,672
−83.28%

If you had invested $10,000 in ARS Pharmaceuticals, Inc. (SPRY) at the close on December 4, 2020, the earliest close on record here, it would have been worth $1,672 at the close on October 21, 2026: −83.28% in total, −26.23% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−64.12%
2025+10.43%
2024+92.52%
2023−35.76%
2022+28.08%
2021−85.63%
2020 (partial year)+85.36%

As of October 21, 2026.

SPRY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$84.28M−$171.30M−203.3%
2024$89.15M$8.00M9.0%
2023$30.00K−$54.37M−181,216.7%
2022$1.32M−$34.68M−2,635.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$84.28M$63.86M−$179.45M−$171.30M−203.3%
2024$89.15M$88.17M−$3.08M$8.00M9.0%
2023$30.00K$30.00K−$67.52M−$54.37M−181,216.7%
2022$1.32M—−$35.52M−$34.68M−2,635.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SPRY Valuation vs Biotechnology Median

Median of 608 stocks
MetricSPRYBiotechnology medianvs median
P/S ratio3.5613.300.3x the median
Profit margin−184.24%−38.31%145.9 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ARS Pharmaceuticals, Inc. (SPRY) is capitalised at $415.69M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 195.

The 52-week range on file runs from $3.81 to $13.15. The most recent close on file for SPRY is $4.18, dated October 21, 2026. That is −$0.11 (−2.56%) against the previous close. The latest close sits 9.71% above that 52-week low.

Financial Health

In fiscal 2025, ARS Pharmaceuticals, Inc. reported revenue of $84.28M. That is −5.46% against the prior fiscal year, when revenue was $89.15M. The same year closed with a net loss of $171.30M. The reported profit margin is −184.24%. That is 145.9 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −2.18.

Across the 4 fiscal years on file, revenue moves from $1.32M in 2022 to $84.28M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 3.56 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −57.78%. Measured over 5 years, that is −14.76% a year compounded. The reported beta is 1.08. Annualized volatility over the trailing 5 years is 79.03%.

Growth & Income

No dividend is on file for SPRY.

The strongest complete calendar year on file is 2024 at +92.52%; the weakest is 2021 at −85.63%. Of the 5 complete calendar years on file, 3 finished higher. So far in 2026 the total return is −64.12%.

Peer Comparison

ARS Pharmaceuticals, Inc. (SPRY) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ARS Pharmaceuticals, Inc. SPRY $415.69M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. ARS Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Visit website →